Abbott Laboratories slips after Q4 topline miss

Abbott Laboratories (NYSE:ABT) traded ~2% lower in the premarket on Wednesday after the diagnostics company’s Q4 2024 results fell short of Street forecasts for revenue despite outperformance in its MedTech division.

North Chicago, Illinois-based Abbott (NYSE:ABT) reported $11B in revenue